These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29445832)

  • 41. Detection of emerging patterns of drug misuse in sports via wastewater monitoring: A mini-review and potential strategies.
    Chang WC; Hsu MC; Liao PC
    Environ Pollut; 2023 Sep; 333():122087. PubMed ID: 37348696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-intentional doping in sports.
    Yonamine M; Garcia PR; de Moraes Moreau RL
    Sports Med; 2004; 34(11):697-704. PubMed ID: 15456345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Annual banned-substance review: Analytical approaches in human sports drug testing 2019/2020.
    Thevis M; Kuuranne T; Geyer H
    Drug Test Anal; 2021 Jan; 13(1):8-35. PubMed ID: 33185038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Annual banned-substance review 16
    Thevis M; Kuuranne T; Geyer H
    Drug Test Anal; 2024 Jan; 16(1):5-29. PubMed ID: 37985429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereoisomers in sports drug testing: Analytical strategies and applications.
    Thomas A; Thevis M
    J Chromatogr A; 2022 Jul; 1674():463154. PubMed ID: 35613502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Annual banned-substance review: analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H; Schänzer W
    Drug Test Anal; 2017 Jan; 9(1):6-29. PubMed ID: 27885819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of the emergence of designer drugs upon sports doping testing.
    Teale P; Scarth J; Hudson S
    Bioanalysis; 2012 Jan; 4(1):71-88. PubMed ID: 22191595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes.
    Mazzarino M; Cesarei L; de la Torre X; Fiacco I; Robach P; Botrè F
    J Pharm Biomed Anal; 2016 Jan; 117():47-60. PubMed ID: 26342446
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The forensic response after an adverse analytical finding (doping) involving a selective androgen receptor modulator (SARM) in human athlete.
    Kintz P
    J Pharm Biomed Anal; 2022 Jan; 207():114433. PubMed ID: 34715583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer.
    Thomas A; Geyer H; Schänzer W; Crone C; Kellmann M; Moehring T; Thevis M
    Anal Bioanal Chem; 2012 May; 403(5):1279-89. PubMed ID: 22231507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents.
    Meyer MR; Maurer HH
    Anal Bioanal Chem; 2012 Jan; 402(1):195-208. PubMed ID: 21866399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analytical aspects in doping control: challenges and perspectives.
    Badoud F; Guillarme D; Boccard J; Grata E; Saugy M; Rudaz S; Veuthey JL
    Forensic Sci Int; 2011 Dec; 213(1-3):49-61. PubMed ID: 21824736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Applications and challenges in using LC-MS/MS assays for quantitative doping analysis.
    Wang Z; Lu J; Zhang Y; Tian Y; Yuan H; Xu Y
    Bioanalysis; 2016 Jun; 8(12):1307-22. PubMed ID: 27241820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenges and threats to implementing the fight against doping in sport.
    Dvorak J; Saugy M; Pitsiladis YP
    Br J Sports Med; 2014 May; 48(10):807-9. PubMed ID: 24764551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing.
    Schänzer W; Guddat S; Thomas A; Opfermann G; Geyer H; Thevis M
    Drug Test Anal; 2013; 5(11-12):810-8. PubMed ID: 23873860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Annual banned-substance review: the Prohibited List 2008-analytical approaches in human sports drug testing.
    Thevis M; Kuuranne T; Geyer H; Schänzer W
    Drug Test Anal; 2009 Jan; 1(1):4-13. PubMed ID: 20355153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigating oral fluid and exhaled breath as alternative matrices for anti-doping testing: Analysis of 521 matched samples.
    Miller GD; Van Wagoner RM; Bruno BJ; Husk JD; Fedoruk MN; Eichner D
    J Pharm Biomed Anal; 2019 Nov; 176():112810. PubMed ID: 31430626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance-Enhancing Drugs I: Understanding the Basics of Testing for Banned Substances.
    Cadwallader AB; Murray B
    Int J Sport Nutr Exerc Metab; 2015 Aug; 25(4):396-404. PubMed ID: 25675030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
    Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in equine anti-doping.
    Cawley A
    Drug Test Anal; 2017 Sep; 9(9):1282-1283. PubMed ID: 28631881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.